Davide Rossi

Research interests

Publications

• Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

  Nature Biotechnology · 2021 · 10.1038/s41587-021-00981-w

• COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

  Leukemia · 2020 · 10.1038/s41375-020-0959-x

• Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.78.5246

• Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

  Blood · 2018 · https://doi.org/10.1182/blood-2017-11-812073

• Diffuse large B-cell lymphoma genotyping on the liquid biopsy

  Blood · 2017 · 10.1182/blood-2016-05-719641

• Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1506583

• Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

  Cancer Cell · 2015 · https://doi.org/10.1016/j.ccell.2015.03.006

• Genetics of Follicular Lymphoma Transformation

  Cell Reports · 2014 · https://doi.org/10.1016/j.celrep.2013.12.027

• Recurrent mutations refine prognosis in chronic lymphocytic leukemia

  Leukemia · 2014 · 10.1038/leu.2014.196

• Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia

  Blood · 2014 · 10.1182/blood-2013-11-539726

• Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome

  Blood · 2013 · 10.1182/blood-2013-03-489518

• Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

  Blood · 2012 · 10.1182/blood-2012-09-458265

• The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development

  The Journal of Experimental Medicine · 2012 · https://doi.org/10.1084/jem.20120904

• Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia

  Blood · 2012 · 10.1182/blood-2011-12-395673

• Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation

  The Journal of Experimental Medicine · 2011 · https://doi.org/10.1084/jem.20110921

• Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

  Blood · 2011 · 10.1182/blood-2010-09-307645

• Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

  Blood · 2011 · 10.1182/blood-2011-08-373159

• The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation

  Blood · 2011 · https://doi.org/10.1182/blood-2010-09-302174

• Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.31.6844

• Inactivating mutations of acetyltransferase genes in B-cell lymphoma

  Nature · 2011 · https://doi.org/10.1038/nature09730

• Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia

  Blood · 2011 · 10.1182/blood-2011-09-379966

• Analysis of the coding genome of diffuse large B-cell lymphoma

  Nature Genetics · 2011 · https://doi.org/10.1038/ng.892

• Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

  Blood · 2010 · https://doi.org/10.1182/blood-2010-07-294983

• Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2010.29.8216

• The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness

  Clinical Cancer Research · 2009 · 10.1158/1078-0432.ccr-08-1630

• Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

  Clinical Cancer Research · 2009 · https://doi.org/10.1158/1078-0432.ccr-08-3266

Current projects

No projects listed.